316 related articles for article (PubMed ID: 30621173)
1. Oversecretion and Overexpression of Nicotinamide Phosphoribosyltransferase/Pre-B Colony-Enhancing Factor/Visfatin in Inflammatory Bowel Disease Reflects the Disease Activity, Severity of Inflammatory Response and Hypoxia.
Neubauer K; Bednarz-Misa I; Walecka-Zacharska E; Wierzbicki J; Agrawal A; Gamian A; Krzystek-Korpacka M
Int J Mol Sci; 2019 Jan; 20(1):. PubMed ID: 30621173
[TBL] [Abstract][Full Text] [Related]
2. Serum Visfatin as a Diagnostic Marker of Active Inflammatory Bowel Disease.
Saadoun MM; Nosair NAE; Abdel-Azeez HA; Sharaf SM; Ahmed MH
J Gastrointestin Liver Dis; 2021 Sep; 30(3):339-345. PubMed ID: 34551033
[TBL] [Abstract][Full Text] [Related]
3. Pre-B cell colony enhancing factor/NAMPT/visfatin and its role in inflammation-related bone disease.
Moschen AR; Geiger S; Gerner R; Tilg H
Mutat Res; 2010 Aug; 690(1-2):95-101. PubMed ID: 19583971
[TBL] [Abstract][Full Text] [Related]
4. Serum adipokines in inflammatory bowel disease.
Waluga M; Hartleb M; Boryczka G; Kukla M; Zwirska-Korczala K
World J Gastroenterol; 2014 Jun; 20(22):6912-7. PubMed ID: 24944482
[TBL] [Abstract][Full Text] [Related]
5. Neutrophil gelatinase-associated lipocalin (NGAL) in inflammatory bowel disease: association with pathophysiology of inflammation, established markers, and disease activity.
Oikonomou KA; Kapsoritakis AN; Theodoridou C; Karangelis D; Germenis A; Stefanidis I; Potamianos SP
J Gastroenterol; 2012 May; 47(5):519-30. PubMed ID: 22200942
[TBL] [Abstract][Full Text] [Related]
6. Nampt/PBEF/visfatin upregulation in colorectal tumors, mirrored in normal tissue and whole blood of colorectal cancer patients, is associated with metastasis, hypoxia, IL1β, and anemia.
Neubauer K; Misa IB; Diakowska D; Kapturkiewicz B; Gamian A; Krzystek-Korpacka M
Biomed Res Int; 2015; 2015():523930. PubMed ID: 26075243
[TBL] [Abstract][Full Text] [Related]
7. Ulcerative colitis, Crohn's disease, and irritable bowel syndrome have different profiles of extracellular matrix turnover, which also reflects disease activity in Crohn's disease.
Mortensen JH; Manon-Jensen T; Jensen MD; Hägglund P; Klinge LG; Kjeldsen J; Krag A; Karsdal MA; Bay-Jensen AC
PLoS One; 2017; 12(10):e0185855. PubMed ID: 29028807
[TBL] [Abstract][Full Text] [Related]
8. The relationship of visfatin/pre-B-cell colony-enhancing factor/nicotinamide phosphoribosyltransferase in adipose tissue with inflammation, insulin resistance, and plasma lipids.
Chang YC; Chang TJ; Lee WJ; Chuang LM
Metabolism; 2010 Jan; 59(1):93-9. PubMed ID: 19765775
[TBL] [Abstract][Full Text] [Related]
9. Systemic interleukin-9 in inflammatory bowel disease: Association with mucosal healing in ulcerative colitis.
Matusiewicz M; Neubauer K; Bednarz-Misa I; Gorska S; Krzystek-Korpacka M
World J Gastroenterol; 2017 Jun; 23(22):4039-4046. PubMed ID: 28652656
[TBL] [Abstract][Full Text] [Related]
10. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease.
D'Haens G; Ferrante M; Vermeire S; Baert F; Noman M; Moortgat L; Geens P; Iwens D; Aerden I; Van Assche G; Van Olmen G; Rutgeerts P
Inflamm Bowel Dis; 2012 Dec; 18(12):2218-24. PubMed ID: 22344983
[TBL] [Abstract][Full Text] [Related]
11. B Cell-Activating Factor as a New Potential Marker in Inflammatory Bowel Disease.
Zhang P; Liu X; Guo A; Xiong J; Fu Y; Zou K
Dig Dis Sci; 2016 Sep; 61(9):2608-18. PubMed ID: 27056038
[TBL] [Abstract][Full Text] [Related]
12. Functional bowel symptoms in quiescent inflammatory bowel diseases: role of epithelial barrier disruption and low-grade inflammation.
Vivinus-Nébot M; Frin-Mathy G; Bzioueche H; Dainese R; Bernard G; Anty R; Filippi J; Saint-Paul MC; Tulic MK; Verhasselt V; Hébuterne X; Piche T
Gut; 2014 May; 63(5):744-52. PubMed ID: 23878165
[TBL] [Abstract][Full Text] [Related]
13. Proteomic analysis of ascending colon biopsies from a paediatric inflammatory bowel disease inception cohort identifies protein biomarkers that differentiate Crohn's disease from UC.
Starr AE; Deeke SA; Ning Z; Chiang CK; Zhang X; Mottawea W; Singleton R; Benchimol EI; Wen M; Mack DR; Stintzi A; Figeys D
Gut; 2017 Sep; 66(9):1573-1583. PubMed ID: 27216938
[TBL] [Abstract][Full Text] [Related]
14. Faecal S100A12 as a non-invasive marker distinguishing inflammatory bowel disease from irritable bowel syndrome.
Kaiser T; Langhorst J; Wittkowski H; Becker K; Friedrich AW; Rueffer A; Dobos GJ; Roth J; Foell D
Gut; 2007 Dec; 56(12):1706-13. PubMed ID: 17675327
[TBL] [Abstract][Full Text] [Related]
15. Faecal Myeloperoxidase as a Biomarker of Endoscopic Activity in Inflammatory Bowel Disease.
Swaminathan A; Borichevsky GM; Edwards TS; Hirschfeld E; Mules TC; Frampton CMA; Day AS; Hampton MB; Kettle AJ; Gearry RB
J Crohns Colitis; 2022 Dec; 16(12):1862-1873. PubMed ID: 35803583
[TBL] [Abstract][Full Text] [Related]
16. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices.
Langhorst J; Elsenbruch S; Koelzer J; Rueffer A; Michalsen A; Dobos GJ
Am J Gastroenterol; 2008 Jan; 103(1):162-9. PubMed ID: 17916108
[TBL] [Abstract][Full Text] [Related]
17. Faecal calprotectin as a novel biomarker for differentiating between inflammatory bowel disease and irritable bowel syndrome.
Chang MH; Chou JW; Chen SM; Tsai MC; Sun YS; Lin CC; Lin CP
Mol Med Rep; 2014 Jul; 10(1):522-6. PubMed ID: 24788223
[TBL] [Abstract][Full Text] [Related]
18. The usefulness of fecal calprotectin in assessing inflammatory bowel disease activity.
Lee YW; Lee KM; Lee JM; Chung YY; Kim DB; Kim YJ; Chung WC; Paik CN
Korean J Intern Med; 2019 Jan; 34(1):72-80. PubMed ID: 29347813
[TBL] [Abstract][Full Text] [Related]
19. Presence of Irritable Bowel Syndrome Symptoms in Quiescent Inflammatory Bowel Disease Is Associated with High Rate of Anxiety and Depression.
Perera LP; Radigan M; Guilday C; Banerjee I; Eastwood D; Babygirija R; Massey BT
Dig Dis Sci; 2019 Jul; 64(7):1923-1928. PubMed ID: 30725303
[TBL] [Abstract][Full Text] [Related]
20. Plasma Extracellular Vesicle LncRNA H19 as a Potential Diagnostic Biomarker for Inflammatory Bowel Diseases.
Heydari R; Fayazzadeh S; Shahrokh S; Shekari F; Farsad F; Meyfour A
Inflamm Bowel Dis; 2024 May; 30(5):795-807. PubMed ID: 37855715
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
